Epilive ER 750 Tablet contains Levetiracetam 750 mg, an antiepileptic agent indicated for the treatment of partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby stabilizing neuronal activity and preventing seizure propagation. The extended-release formulation allows for once-daily dosing, improving patient compliance by maintaining steady plasma concentrations over 24 hours. Epilive ER 750 is typically prescribed as adjunctive therapy in adults and pediatric patients aged 16 years and older; dosage adjustments may be necessary based on renal function and clinical response. Common adverse effects include somnolence, dizziness, fatigue, and headache, though it is generally well tolerated. Caution is advised in patients with a history of psychiatric disorders, as mood changes and behavioral symptoms have been reported. Epilive ER 750 should be used under medical supervision with regular monitoring to optimize therapeutic outcomes and minimize potential side effects. It is contraindicated in patients with known hypersensitivity to Levetiracetam or any of the tablet excipients. This medication should not be discontinued abruptly to avoid risk of increased seizure frequency.